{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-072258","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.509296+00:00","generated_at":"2026-06-07T09:17:44.364064+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Galecto reports positive Phase 2a myelofibrosis data; fibrosis reduction in 6 of 10 evaluable patients","bullets":["6 of 10 evaluable myelofibrosis patients on GB2064 monotherapy ≥6 months had ≥1-grade reduction in bone marrow collagen fibrosis.","All 6 patients with fibrosis reduction maintained stable hematological parameters (hemoglobin, WBC, platelets).","One patient achieved ≥35% spleen volume reduction; two reduced Total Symptom Score >50%; one had anemia response.","Four patients entered extension due to clinical benefit; one on treatment >30 months; GI adverse events manageable.","Company will not decide on further GB2064 trials until completion of strategic alternative process."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-072258","json":"https://secwatch.observer/filing/0000950170-23-072258.json","markdown":"https://secwatch.observer/filing/0000950170-23-072258.md","text":"https://secwatch.observer/filing/0000950170-23-072258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000095017023072258/0000950170-23-072258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000095017023072258/glto-20231221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:17:44.364064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}